Evidence map›Paper›PMID 35126865›Full record

ArticleOncotarget2022

Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers.

Ami N Shah, Ashwin Sunderraj, Brian Finkelman, Sharlene H See, Andrew A Davis, Lorenzo Gerratana, Firas Wehbe, Neelima Katam, Deva Mahalingam, William J Gradishar and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ami N ShahRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Ashwin SunderrajRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Brian FinkelmanDepartment of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Sharlene H SeeRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Andrew A DavisSiteman Cancer Center of Washington University, St. Louis, MO, USA.
Lorenzo GerratanaDepartment of Medical Oncology, Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, Italy.
Firas WehbeRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Neelima KatamRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Deva MahalingamRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
William J GradisharRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Amir BehdadRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Luis BlancoRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Massimo CristofanilliRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe correlation of ERBB2 copy number gain (CNG) from tissue or circulating tumor DNA (ctDNA) by next-generation sequencing (NGS) with standard HER2 tissue evaluation is not well understood. MATERIALS AND

methodsWe retrospectively identified patients with ERBB2 CNG on commercial NGS. We described their clinical-pathologic features and calculated the positive predictive value (PPV) of ERBB2 CNG by NGS for HER2-positivity by IHC and FISH testing.

results176 patients had NGS revealing an ERBB2 CNG (112 by tumor tissue and 91 by ctDNA). The cancer subtypes with the most cases with ERBB2 CNG by NGS were breast (

conclusionsERBB2 CNG by NGS is detected in numerous malignancies for which HER2 testing is not standard. Detection of ERBB2 CNG by tissue NGS and ctDNA has a high PPV for true HER2-positivity by standard IHC and/or FISH testing in breast cancer.

Indexed as

Circulating Tumor DNANeoplasmsBiomarkers, TumorDNA Copy Number VariationsErb-b2 Receptor Tyrosine KinasesHigh-Throughput Nucleotide SequencingHumansPredictive Value of TestsRetrospective StudiesBiomarkers, TumorCirculating Tumor DNAERBB2 protein, humanErb-b2 Receptor Tyrosine Kinasescirculating tumor DNAcopy number gainERBB2HER2next-generation sequencing

Identifiers

PMID35126865
PMCPMC8809397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.